These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7391081)

  • 1. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate.
    Silverberg M; Dunn JT; Garen L; Kaplan AP
    J Biol Chem; 1980 Aug; 255(15):7281-6. PubMed ID: 7391081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein.
    Dunn JT; Silverberg M; Kaplan AP
    J Biol Chem; 1982 Feb; 257(4):1779-84. PubMed ID: 6915937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation and structure of human Hageman factor fragments.
    Dunn JT; Kaplan AP
    J Clin Invest; 1982 Sep; 70(3):627-31. PubMed ID: 6921203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
    Kaplan AP
    Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The autoactivation of rabbit Hageman factor.
    Wiggins RC; Cochrane CC
    J Exp Med; 1979 Nov; 150(5):1122-33. PubMed ID: 501286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor).
    Tans G; Rosing J; Griffin JH
    J Biol Chem; 1983 Jul; 258(13):8215-22. PubMed ID: 6553053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein.
    Wiggins RC
    J Biol Chem; 1983 Jul; 258(14):8963-70. PubMed ID: 6553057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII).
    Silverberg M; Kaplan AP
    Blood; 1982 Jul; 60(1):64-70. PubMed ID: 6979361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
    Revak SD; Cochrane CG; Griffin JH
    J Clin Invest; 1977 Jun; 59(6):1167-75. PubMed ID: 864009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on prekallikrein of bovine plasma. II. Activation of prekallikrein with proteinases and properties of kallikrein activated by bovine Hageman factor.
    Takahashi H; Nagasawa S; Suzuki T
    J Biochem; 1980 Jan; 87(1):23-34. PubMed ID: 6766924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.
    Revak SD; Cochrane CG; Bouma BN; Griffin JH
    J Exp Med; 1978 Mar; 147(3):719-29. PubMed ID: 632748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of C1 inhibitor upon Hageman factor autoactivation.
    Weiss R; Silverberg M; Kaplan AP
    Blood; 1986 Jul; 68(1):239-43. PubMed ID: 3487356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The autoactivation of factor XII in the presence of long-chain saturated fatty acids--a comparison with the potency of sulphatides and dextran sulphate.
    Mitropoulos KA; Esnouf MP
    Thromb Haemost; 1991 Oct; 66(4):446-52. PubMed ID: 1796394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of human Hageman factor by a leukocytic protease.
    Newball HH; Revak SD; Cochrane CG; Griffin JH; Lichtenstein LM
    Adv Exp Med Biol; 1979; 120B():139-51. PubMed ID: 517231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular assembly in the contact phase of the Hageman factor system.
    Cochrane CG; Griffin JH
    Am J Med; 1979 Oct; 67(4):657-64. PubMed ID: 386794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates.
    Cho K; Tanaka T; Cook RR; Kisiel W; Fujikawa K; Kurachi K; Powers JC
    Biochemistry; 1984 Feb; 23(4):644-50. PubMed ID: 6370301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis.
    Mandle R; Kaplan AP
    J Biol Chem; 1977 Sep; 252(17):6097-104. PubMed ID: 408348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
    Kaplan AP; Joseph K
    Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of activation and autoactivation of human factor XII.
    Tankersley DL; Finlayson JS
    Biochemistry; 1984 Jan; 23(2):273-9. PubMed ID: 6607744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hageman factor dependent pathway in local vascular permeability enhancement.
    Yamamoto T; Kozono K; Tsuruta J; Cochrane CG; Kambara T
    Adv Exp Med Biol; 1986; 198 Pt B():45-52. PubMed ID: 3812107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.